IFNA1 and myeloid sarcoma: The factor-containingsupernatants from healthy donors reduced the stimulatory action ofautologous IFNs in patients with MS almost until complete blockade.Because this inhibitor was absent in patients with MS, deficiency ofan inhibitor of IFN regulatory action in MS could open the way totreatment of this compartment of the immune system.